Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 16Sarcoma 5Lymphoid 2Breast 2Tumor-Agnostic 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Specimen Handling 49Letrozole 42Fulvestrant 42Paclitaxel 38pembrolizumab 34Magnetic Resonance Spectroscopy 31Carboplatin 31ribociclib 26Trastuzumab 26Biopsy 26exemestane 23Anastrozole 23Capecitabine 22palbociclib 21pertuzumab 20Tamoxifen 19trastuzumab deruxtecan 18abemaciclib 18Cyclophosphamide 17Taxes 15Radiotherapy 14130-nm albumin-bound paclitaxel 12elacestrant 11Docetaxel 11sacituzumab govitecan 9olaparib 9Standard of Care 9Radiation 9Goserelin 9Gemcitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
liposomal doxorubicin × Breast × 30 days × Clear all
NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,000 enrolled
Breast

Breast Neoplasms

NCT06312176 2026-05-22

MK-2870-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,200 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡